Occupier

Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

You can also keep up to date by following us on Twitter or LinkedIn

Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage

15 May 2023

Third clinical molecule from collaboration with Sumitomo Pharma to enter Phase 1 trials DSP-2342, a dual 5-HT2A/5-HT7 antagonist to be assessed in psychiatric disease OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced that Sumitomo Pharma Co., Ltd. (‘Sumitomo Pharma’) plans to initiate a Phase 1 clinical study of DSP-2342 in the United States. DSP-2342 is a highly-selective bispecific small molecule with... Read more

OrganOx Chief Medical Officer, Professor Peter Friend, Elected as Vice President of Royal College of Surgeons of England

12 May 2023

Oxford, United Kingdom, 12 May 2023: OrganOx Ltd (“OrganOx” or the “Company”), a world-leading medical technology company committed to making every donated organ count with metra®, a fully automated normothermic machine perfusion (NMP) device for liver transplantation, today announces that Chief Medical Officer, Professor Peter Friend, has been elected as Vice President of the Royal College of Surgeons of England. Professor Friend, a... Read more

Professor Andrew L. Hopkins elected Fellow of the Royal Society

10 May 2023

Professor Andrew L. Hopkins elected Fellow of the Royal Society May 10, 2023 Changing the world through exceptional science and technology OXFORD, England--(BUSINESS WIRE)-- Professor Andrew Hopkins DPhil LLD FRSE, founder and Chief Executive of Exscientia plc (Nasdaq: EXAI), has been elected a Fellow of the Royal Society, the world’s oldest and most influential scientific society. Andrew is one of the UK’s most eminent science and... Read more

Exscientia Appoints Harvard Professor Franziska Michor, Ph.D. to Board of Directors

03 May 2023

— Renowned thought leader in computational biology and data science for cancer research — — Over 180 publications on the evolutionary dynamics of cancer initiation, progression, response to therapy and emergence of resistance — OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced the appointment of Professor Franziska Michor, Ph.D. to its Board of Directors. Prof. Michor is a professor of Computational Biology... Read more

Oxford Nanopore and bioMérieux to enter into a strategic partnership agreement to develop innovative infectious disease diagnostics

14 Apr 2023

Oxford Nanopore and bioMérieux to enter into a strategic partnership agreement to develop innovative infectious disease diagnostics Fri 14th April 2023 Oxford Nanopore Technologies and bioMérieux SA, a world leader in the field of in vitro diagnostics, today announced that they have teamed up to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics... Read more

News